GSK plc (GSK) on Monday said China's National Medical Products Administration has approved Blenrep in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory Multiple Myeloma who have received at least one prior line of therapy.
The approval is supported by data from the pivotal Phase III DREAMM-7 trial, which showed statistically significant and clinically meaningful improvements in progression-free survival and overall survival for the Blenrep combination compared with a daratumumab-based regimen with bortezomib and dexamethasone.
GSK said the safety and tolerability profile of the Blenrep combination was broadly consistent with the known profiles of the individual medicines.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.